(Adnkronos) - In questo numero:
Aids: solo 1 giovane su 2 si protegge. I dati dell’osservatorio Durex
Antibiotico resistenza, a Bari l'evento conclusivo del G7 Salute. Gemmato: "Investimenti strutturali dal Governo"
Tumore del polmone, Fondo farmaci innovativi importante ma va migliorato
Promuovere tecnologia a mRna, a Venezia l’incontro per un documento condiviso
Malattie croniche, in Italia costano 65 miliardi all'anno
Nuova opzione terapeutica per il linfoma diffuso a grandi cellule B
A Roma l’incontro sulla cheratite da Acanthamoeba per diffondere conoscenza su grave e rara patologia oculare
Presentato il Libro bianco 'Hiv Le parole per tornare a parlarne’
Malattie infiammatorie croniche intestinali, importanti novità grazie a guselkumab
Inaugurato a Bari il Villaggio della Salute: per tre giorni workshop e visite mediche
Conclusa la 19° edizione del Forum risk management di Arezzo
Presentato studio sull’impatto del settore farmaceutico che vede protagoniste AstraZeneca e Alexion
Congresso Ig-Ibd, malattie infiammatorie croniche intestinali in crescita ma terapie più efficaci
One Health Ambassador: premiati 102 professionisti per un nuovo modello di salute globale
Aids: solo 1 giovane su 2 si protegge. I dati dell’osservatorio Durex
Antibiotico resistenza, a Bari l'evento conclusivo del G7 Salute. Gemmato: "Investimenti strutturali dal Governo"
Tumore del polmone, Fondo farmaci innovativi importante ma va migliorato
Promuovere tecnologia a mRna, a Venezia l’incontro per un documento condiviso
Malattie croniche, in Italia costano 65 miliardi all'anno
Nuova opzione terapeutica per il linfoma diffuso a grandi cellule B
A Roma l’incontro sulla cheratite da Acanthamoeba per diffondere conoscenza su grave e rara patologia oculare
Presentato il Libro bianco 'Hiv Le parole per tornare a parlarne’
Malattie infiammatorie croniche intestinali, importanti novità grazie a guselkumab
Inaugurato a Bari il Villaggio della Salute: per tre giorni workshop e visite mediche
Conclusa la 19° edizione del Forum risk management di Arezzo
Presentato studio sull’impatto del settore farmaceutico che vede protagoniste AstraZeneca e Alexion
Congresso Ig-Ibd, malattie infiammatorie croniche intestinali in crescita ma terapie più efficaci
One Health Ambassador: premiati 102 professionisti per un nuovo modello di salute globale
Category
🗞
NewsTranscript
00:00In this number, AIDS, only 1 out of 2 young people are protected, according to the Durex Observatory.
00:17Antibiotic resistance, the final event of the G7 health,
00:22structural investments from the government, lung tumor, important innovative pharmaceutical fund, but must be improved,
00:30promote mRNA technology, in Venice the meeting for a shared document,
00:37chronic diseases, in Italy they cost 65 billion a year,
00:42and again, new therapeutic option for lymphoma spread to large B cells,
00:48in Rome the meeting on keratitis dacantamoeba, to spread knowledge on serious and rare eye pathology.
00:55Presented the white book HIV, the words to go back to talk about it.
01:01Inflammatory, chronic, intestinal diseases, important news, thanks to Guselcumab.
01:07Inaugurated in Bari, the village of health, for 3 days, workshops and medical visits.
01:13Concluded the 19th edition of the forum Risk Management of Arezzo.
01:18Presented a study on the impact of the pharmaceutical sector, which sees protagonists AstraZeneca and Alexion.
01:25IGBD Congress, inflammatory, chronic and intestinal diseases in growth, but more effective therapies.
01:32One Health Ambassador, awarded 102 professionals for a new global health model.
01:43On a sample of 15,000 young people between 11 and 24 years, almost 1 in 2, equal to 47.6%,
01:50can not recognize sexually transmitted infections, called IST.
01:56Among sexually active young people, 2 in 3 have never done a test for IST and HIV.
02:02Less than 1 in 2 young people, 44%, usually uses the condom,
02:07a figure that drops to 1 in 4 in the 11-13 year range.
02:12In addition, almost 5 out of 10 young people do not know that it is the only contraceptive method
02:17able to protect from the spread of such infections.
02:20It is the photo taken by the Durex Youth and Sexuality Observatory.
02:24Reached the 7th edition, the analysis, carried out annually in collaboration with scuola.net,
02:30was presented in Milan on the occasion of the World Day Against AIDS.
02:35The number of sexually transmitted infections is on the rise,
02:40we are talking about a percentage even above 30%,
02:45and this clearly opens up a very broad discussion
02:50on what are the behaviors and awareness behind the sexually transmitted infections.
02:57For 7 years now, with the Observatory,
03:00we analyze the percentage of young people who regularly use the condom.
03:09Also this year, the 7th year of our Observatory, we see that this percentage drops.
03:14Fundamental for young people is the support of school and family.
03:18Unfortunately, Italy is one of the few countries in the European Union
03:21that still does not see sexual education as an essential tool within schools.
03:28As for families, they should also have an important role,
03:32but unfortunately, from the Observatory data, it emerges that only a few young people
03:37really recognize the family as a reference point for everything that concerns their affectivity and sexuality.
03:46Durex's commitment to the awareness of free, protected and conscious sexuality is constantly active.
03:54First of all, we have launched a program called Luce Accese,
03:58which is a program that aims to shed light on this discomfort of our young people
04:05in the lack of information or reference points regarding sexual and affective education.
04:12Finally, with the Italian Red Cross, we have created a partnership
04:18in which we not only distribute educational and informative materials
04:24regarding sexuality and sexual education, but we also give free condoms.
04:34We distribute these free condoms, we have recently distributed 120,000
04:39in order to promote behaviors that are not at risk and that are therefore protected.
04:4935,000 deaths caused each year in Europe, about 12,000 only in Italy,
04:53and the antibiotic resistance is the theme at the center of the G7 health event in Bari,
04:58a two-day event dedicated to what the Ministry of Health has identified as one of its priorities
05:03in the agenda of the Italian presidency of the G7.
05:06The first day saw preliminary comparisons between the medical-scientific community,
05:10health professions and the pharmaceutical industry, the first subjects involved in the issue,
05:15to explain what has already been done by the institutions in Italy,
05:18instead, the Deputy Secretary of Health, Marcello Gemmato,
05:21has thought about it.
05:23On the one hand, in fact, the use of antibiotics in the zootechnical line,
05:26which represents about 50% of the problem, is in a sensitive reduction
05:30thanks to the tracking of the medicines allowed by the electronic prescription.
05:34On the other hand, the government is allocating important resources
05:37to strategies aimed at encouraging good practices.
05:41The government has already, in the triennial plan of contrast to the antibiotic resistance,
05:45invested 40 million euros per year, therefore a structural investment,
05:49to fight the antibiotic resistance.
05:52In addition, Minister Giorgetti and Minister Schillaci in Ancona
05:57have announced the investment of 21 million euros in the so-called PUSH mechanism,
06:03then sustainability in investment and research.
06:07The government, according to the balance sheet,
06:09has invested 100 million euros for the so-called reserve antibiotics,
06:13that is, antibiotics designed to cure the pathologies
06:17for which there is currently no therapeutic alternative.
06:20The role of the institutions will therefore be fundamental.
06:22It is no coincidence that one of the in-depth studies
06:24has been dedicated to the policies to be put into perspective after the G7 meetings.
06:28There is the awareness of an extraordinary emergency
06:31that can cause millions of deaths in the long run.
06:35The path that goes through the government is the correct one,
06:38a global approach that includes a strategy that is coordinated with all European countries
06:44and in particular are campaigns of awareness, but also investments in research.
06:55A collective strategy to fight lung cancer.
06:59Between innovative drugs, the state fund that makes them available
07:02and the choices to make to make them even more efficient.
07:05This was discussed at the national convention promoted by MSD Italy
07:09on the contribution of innovation to the treatment of lung cancer.
07:13The right time to present two investigations such as that of BVA DOXA,
07:17the lung cancer between needs of knowledge and fake news,
07:21and the IHE report, the Swedish Institute for Health Economics,
07:25on access to innovative oncological drugs in Italy.
07:28We are the first biopharmaceutical company in the world for research intensity,
07:3342% of our revenues, which means over 30 billion dollars invested in research and development last year,
07:41which also equate to our 105 million euros, which are very important
07:47as they are compared to a total of 700 million euros invested in research and development
07:51by the entire pharmaceutical sector in Italy.
07:55It means, as innovation, access to innovation immediately to patients
08:00and above all the opportunity to be truly included in what is the great engine of research.
08:07A research that is the heart of therapies,
08:09at the forefront of how our fund for the realization of these innovative drugs
08:13is at the epicenter of everything and also represents a model in Europe.
08:17For the record, our country has a reimbursability rate equal to 83%,
08:22higher than the European average.
08:24As they are better, also the access times to the same treatments,
08:27after EMA approval, 417 days compared to 559.
08:32Only that in 2023, 35% of the funds were left unused,
08:37spending only 770 million on 1.2 billion.
08:41We still record 44,000 new cases a year.
08:46This tumor still has a close link with cigarette smoke.
08:50The introduction of molecular-target drugs and the introduction of immunotherapy
08:55have radically changed our treatment algorithm,
09:00which means that patients receive these treatments,
09:04have a discreet quality of life and have a much longer life expectancy
09:10compared to what we could get with only chemotherapy.
09:14But in such an important battle, we cannot stop.
09:17For this reason, Anna Maria Mancuso, President and CEO of ODV
09:20and coordinator of the group La Salute, Un Bene da Difendere, Un Diritto da Promuovere,
09:24has indicated the way to ensure a further step forward.
09:28The access times are quite long, I would say.
09:33Just think that they pass between levels, that is, EMA, AIFA and regions.
09:40This amendment provides for the extension of the possibility within AIFA
09:46to consider an innovative drug within 10 years, not 6,
09:51as a limit to what is now considered.
09:59A moment of sharing and debate between institutions, associations and health professionals,
10:04starting from the territory, in order to make a document
10:08in which guidelines are divided that promote the use of mRNA technology in public health.
10:13This is the goal of the Expert Advisory Panel,
10:16the innovation of mRNA technology, from scientific potential
10:20to opportunities for regional health, held in Venice.
10:24This technology has shown to be winning, especially in some aspects.
10:31First of all, the speed of introduction.
10:34So, certainly for the regional system, it is an opportunity to manage
10:40in a tempestuous way the new challenges that come in our regional scenario,
10:46but also, of course, national.
10:48mRNA technology makes it possible to prevent, in a simpler and more effective way,
10:52some of the main pathologies and objects of the vaccination campaigns.
10:56The innovation of mRNA, certainly, can lead to the arrival of new technologies,
11:03with new combinations, can lead to an increase of what are the vaccination coverage
11:08and, therefore, in my opinion, it could somehow reduce the burden of many pathologies
11:14that afflict our population at the moment, especially the most fragile.
11:19The advent of this new technology, therefore, leads to the need to review and implement
11:23the vaccination calendar, in a view not only of greater coverage efficiency,
11:27but also of equal access.
11:29I believe that it is absolutely necessary to consider the expansion of the vaccination calendar.
11:35It is clear that it is also necessary to do a job that is sustainable in all regions,
11:44because, otherwise, population disparities are created.
11:47Therefore, availability must also be considered,
11:50and this is a topic that must be considered on a large scale.
11:55Also important in this sense is the role of the doctors of general medicine,
11:58a health presidium close to the citizens.
12:01For years now, family doctors are ready to face the various vaccination campaigns
12:09through the historical implementation of an organized vaccination school,
12:15both at the union level and at the level of scientific societies.
12:19Therefore, as a category, this new technology also sees us a bit at the forefront.
12:25It is about continuing the path of training of individual colleagues,
12:30making them increasingly aware of these potentials.
12:39In Italy, 24 million people live with chronic diseases,
12:43responsible for 85% of deaths and a health expense of over 65 billion euros per year.
12:51Pathologies such as heart failure, type 2 diabetes and chronic renal disease
12:57are increasing, accomplices of population aging and delays in diagnosis prevention.
13:03To face this challenge, European House Ambrosetti, with the support of AstraZeneca,
13:09has carried out an innovative project, six regional roundtables with over 40 experts,
13:15to redesign the management of cardiometabolic chronicity.
13:19The results, presented during the event
13:22«Ripensare le cronicità all'impatto dell'innovazione per un sistema sanitario nazionale sostenibile»
13:27that took place in Rome, underline the crucial role of pharmaceutical innovation
13:32to improve the lives of patients and guarantee the sustainability of the national health service.
13:38I focus on chronic renal disease.
13:41Chronic renal disease, which is epidemic today, is the main degenerative chronic disease
13:47that has a number of patients from 2 to 7 times higher than other chronic diseases
13:53such as diabetes, neoplasia, cardiopathy and chronic respiratory diseases.
14:00This disease has a huge negative impact on the patient's survival.
14:05Think that a 40-year-old patient who is in dialysis has the same life expectancy
14:09as a patient of the same age of 80 years without disease.
14:13This disease costs a lot.
14:15It costs 50,000 euros in the dialysis phase,
14:18so Italy spends 2.5 billion euros per year for 45,000 dialysis patients.
14:26Today we can treat it, we can put this disease in remission
14:29through glyphosate and other drugs that are already available.
14:35We can extend the life of these patients without dialysis to 20 years.
14:39The problem is that we have to be able to see and treat these patients.
14:44Therefore, the early recognition of this disease is essential
14:48because it is an asymptomatic disease in the initial stages.
14:51Only 10% of patients know they have the disease and therefore turn to the nephrologist.
14:57Therefore, a screening program is very important.
15:00As the Italian Society of Nephrology, we have asked and obtained
15:05that a law has been submitted at the national level,
15:08at the level of Montecitorio, by the Vice-President of the Chamber,
15:11the Honorable Moulet, on the screening and treatment of this disease
15:15in general medicine ambulatories.
15:17Therefore, to create a network between general medicine and nephrology specialists.
15:23Only in this way will we be able to implement therapies with glyphosate
15:29and finally put this disease in remission.
15:33A fundamental role in care and prevention is then played by pharmacies.
15:38Certainly, the role of the pharmacist is very important.
15:41The increase in chronicity, the ability of companies to make available new tools of care
15:47are two elements that must make us reflect on the tension we all have
15:52to maintain a balanced national health service,
15:54therefore able to assist citizens as we are doing now.
15:59In this sense, the pharmacy of services,
16:01the pharmacists in the pharmacy of services,
16:03can contribute to help the doctor, also in the light of the DM77,
16:08therefore this need to make a team in favor of the citizen,
16:11to be able to put into practice with the alter pessori,
16:16the electrocardiogram, the blood capillary sample,
16:20a series of first tests that can be useful to the doctor
16:24to frame the eventual development of a therapeutic approach for the patient.
16:32What is the new treatment?
16:35The Star Hotel Excelsior event titled Amazing New Treatment Option for RR-DL-BCL
16:39was recently held in Bologna,
16:44promoted by SOBI,
16:46to which the most authoritative hematologists and hematologists
16:50at the national and international level have participated.
16:53The topic at the center of the debate is a new treatment for the lymphoma
16:57diffuse B-cell lymphoma,
16:59LONCASTUXIMAB DESIRINE,
17:01which entered clinical practice in Italy in March of this year,
17:05as a treatment for adult patients with B-cell diffuse lymphoma
17:10and high-degree B-cell lymphoma,
17:13recidive or refractory,
17:15after two or more lines of systemic therapy.
17:18This is a drug that has entered the therapeutic approach
17:23for patients with B-cell diffuse lymphoma
17:26and high-degree B-cell lymphoma.
17:28It is an anti-CD19 drug,
17:30that is, it is a cytotoxic substance
17:32that directly supports the antibody
17:37on the cell surface of the neoplastic or lymphatic cell,
17:42because it presents the anti-CD19 antigen,
17:45and at that point there is a linker,
17:47like a trap,
17:49that enters, penetrates, creates a hole in the cell wall of the neoplastic cell,
17:55where the cytotoxic substance is discharged,
17:58so it is a truly direct action on the neoplastic cell.
18:03Lymphomas are malignant tumors of the blood
18:06that derive from an abnormal growth of lymphocytes,
18:09the cells of the immune system
18:11that protect the body from infections and tumors.
18:14Diffuse large B-cell lymphoma
18:16is the most common type of non-Hodgkin lymphomas.
18:21It is generally considered an aggressive lymphoma,
18:25which generally means that the lymphoma cells are fast-growing.
18:30Patients generally present with symptoms.
18:35If you don't treat the disease,
18:39patients generally have poor outcomes.
18:43Diffuse large B-cell lymphoma
18:45being the most common non-Hodgkin lymphoma in the United States,
18:49there are about 20,000 to 25,000 cases of diffuse large B-cell lymphoma every year.
18:56In Italy, there are about 4,000 to 5,000 new cases of diffuse large B-cell lymphoma.
19:03Despite the large B-cell lymphoma,
19:08we are witnessing an extraordinary improvement of the prognosis
19:16thanks to the availability of numerous drugs and treatments available for these patients in the last five years.
19:24Unfortunately, we still can't cure them all.
19:29Therefore, we welcome the new approvals,
19:35such as the latest one obtained in the third line,
19:39the Oncastuximab,
19:42which gives the opportunity to treat patients
19:47who have already been heavily pre-treated,
19:50who have received more than two lines of treatment.
19:53The vast majority of these patients are elderly,
19:57in any Italian hematology,
20:02because the therapies approved in the third line,
20:06such as the B-specific and the SS-CART-T,
20:08if they have not been used in the second line,
20:10are not easily accessible to all centers,
20:16because the CART-T centers are limited.
20:19Therefore, those who are not CART-T centers
20:21do not have the expertise or the organization to be able to use the B-specific.
20:27Well, the Oncastuximab is an effective treatment
20:32that works very quickly when it works,
20:36and we have already seen it within two months,
20:40which is quite tolerable.
20:45Moreover, it is easily accessible,
20:48it does not require recovery,
20:50and it is a time-finished therapy.
20:56Violent pain, blurred vision, photophobia and abundant cremation,
21:00these are the main manifestations of keratitis dacanthomeba,
21:03a serious parasitic eye infection,
21:05of which the improper use of contact lenses is responsible
21:08in more than 80% of cases,
21:10and which, if not temporarily diagnosed and treated,
21:13can lead to blindness.
21:15To increase the knowledge of the pathology
21:17and the awareness of the risks associated with it,
21:19by reviewing the central role of prevention and early diagnosis,
21:22the Dialogue Meeting was held in Rome,
21:24promoted by the Italian Health Policy Brief magazine
21:28and organized in collaboration
21:30with the Alliance for the Equity of Access to Cures for Eye Diseases.
21:33In the suspicion of dacanthomeba,
21:35certifications have to be made,
21:37which are the confocal microscopy
21:39and the sample for microbiological tests,
21:41because treated in that phase,
21:43the effectiveness of the treatment is very high.
21:45If you wait, when the cysts,
21:47when the parasite deepens in the cornea,
21:49the treatment becomes much more problematic.
21:51The therapy is based on two antiseptics,
21:54which are chlorexidine and PHMB,
21:56approved by the European Agency EMA,
21:59and now we are waiting for the approval of AIFA
22:01and we hope that it arrives on the market soon.
22:04The meeting was a moment of confrontation
22:06that has seen the recommendations and proposals
22:08of the medical-scientific community,
22:10of the patient associations, but also of politics.
22:12Precious indications were enclosed in a social manifesto
22:15to raise awareness of health workers
22:17about this ultra-rare and serious disease.
22:19The purpose of this manifesto
22:21is to raise awareness of public opinion,
22:24in particular health workers,
22:26but also citizens,
22:28because this disease can be prevented,
22:30not only by curing with this new medicine,
22:33this polyhexanide,
22:35which was developed by an Italian pharmaceutical company,
22:39but it can be prevented,
22:41so prevention is also the purpose of this manifesto.
22:45In the transformative scope of the advent of polyhexanide,
22:48the first drug aimed at treating keratitis by Cantomeba,
22:51the result of the work of Italian research and development,
22:54two needs are also supported,
22:56early diagnosis and patient care.
22:59All activities that can be supported by politics,
23:02starting from the Intergroup that I preside,
23:04on eye diseases,
23:06which deals particularly with these rare diseases,
23:09because they are often unknown diseases
23:11that require special attention.
23:14It is therefore essential to disseminate information
23:16on this pathology,
23:17so as to help patients to add the correct diagnosis
23:19in a short time,
23:21avoiding serious effects,
23:23as Alice Sotero, the penta-athlete, says.
23:25I obviously went to my reference oculist,
23:28who treated me for an herpes,
23:31because the year before I had an herpes
23:34and I thought of a recidiva.
23:36Subsequently, he sent me to other colleagues
23:39because I did not respond to the therapies.
23:41I was sent to Grosseto by Professor Sarnicola,
23:44where I did an eye scrapping
23:46and where they actually found the positivity
23:49of the keratitis by Cantameba.
23:51From that moment on, I started the treatments.
23:54The pains were very strong,
23:56because it had been two weeks since I had the disease.
23:59I had an ulcer that caused me a lot of pain.
24:02I was bedridden for a long time,
24:04because the anti-inflammatories, the painkillers,
24:06did not have any effect.
24:08Gradually, through the therapy,
24:11the pains were reduced
24:13and I was able to resume training
24:15and my way to Paris.
24:21According to the Institute of Health,
24:23there are more than 2,000 new HIV-infection diagnoses
24:27that interest the Italian population every year.
24:30Yet, only 16% of Italians
24:33claim to be very informed on the subject.
24:36Italians are still confused
24:38about the transmission modes of the virus
24:40and 63% of them feel at no risk of contracting HIV.
24:45These are just some of the data
24:47from a demoscopic survey
24:49carried out by Astra Research for Gilead Science
24:53on a sample of over 1,500 people between the ages of 18 and 70.
24:57Data reported in the white book HIV,
25:01the words to go back to talk about it.
25:04Presented in Rome at the HIV event
25:07from the words to the actions,
25:09together to end the epidemic.
25:11There is a great need to increase prevention,
25:14to adopt new tools,
25:16because one of the key points of the fight against HIV
25:19is an indispensable tool
25:21to be able to get to the zero of which we are talking about,
25:24of the 2039 diagnosis.
25:26In many European countries there is this stigma
25:29on the part of health workers,
25:31workers who still assist people.
25:33I think this is a great battle
25:35because the stigma moves people away from the test,
25:37moves people away from places of care.
25:39From the investigation also emerges little information
25:42on the prevention strategies of pre-exposure prophylaxis,
25:45the so-called PREP,
25:47known only by 6% and 7% of the interviewees
25:51and services that can be found in the checkpoints,
25:54territorial prisons of which 56% and 5% of Italians
25:58do not know the existence.
26:00The checkpoints, working with the communities,
26:03because full of people who belong directly to these communities,
26:08allow an equal approach
26:10that brings people together,
26:12breaks down barriers
26:14and allows us to do a very important job
26:17to serve these communities
26:20and try to contribute to the fight against HIV
26:24and transmissible diseases.
26:26Four, the keywords of the white book HIV,
26:29the words to go back to talk about it,
26:31prevention, stigma, checkpoints and quality of life.
26:34Certainly, together with all the actors,
26:38companies, institutions,
26:41researchers, the medical community,
26:44the community, we must continue to make the difference,
26:48both in terms of diagnosis,
26:52in terms of prevention,
26:54in terms of treatment,
26:56but also, as we have seen today, there is a lot of ignorance.
26:59At the event organized in Rome,
27:01doctors, associations and institutions
27:04took part to redefine the agenda of priorities.
27:06What we are asked for is a new law
27:11that innovates the 135 of the 90
27:14and that gives the country new tools
27:18to fight HIV, AIDS, HPV and sexually transmitted diseases.
27:27In Italy, 250,000 people are forced to live
27:31with inflammatory and chronic intestinal diseases.
27:34For them, a new hope comes from Guselcumab,
27:37a biological treatment that selectively inhibits
27:40a subunit of Interleukin-23,
27:43which continues to prove to be an effective and safe therapy
27:46both in ulcerative colitis and Crohn's disease.
27:49Surely, Guselcumab represents a step forward,
27:53a step towards personalization of the treatment,
27:57flexibility, both in terms of dosage
28:00but above all in terms of supply
28:03both in subcutaneous and endovenous form.
28:08It will allow our patients to choose the treatment
28:12according to their needs.
28:14This is a very important factor
28:16that will bring us closer and closer
28:19to be able to treat patients
28:21on the basis of their needs
28:24in the field of personalized medicine.
28:27It is important to underline
28:29how the treatment of Guselcumab
28:32is a treatment that is able to achieve goals
28:35that are more and more complicated,
28:38more and more ambitious.
28:40There are composite goals,
28:42such as endoscopy in association with histology,
28:46which is fundamental, especially in ulcerative colitis,
28:49and how the maintenance of these goals is long-term.
28:53Johnson & Johnson has presented the important news
28:56on the occasion of the Riccione Congress
28:59of the Italian Group of Inflammatory Bowel Disease.
29:02In the Quasar study, which evaluated the effectiveness
29:05and safety of Guselcumab in patients
29:07with moderately serious ulcerative colitis,
29:10it was shown that after a year of treatment
29:13up to 35% of patients with ulcerative colitis
29:16reached a very important endpoint,
29:19which was that of mucosal healing.
29:21Endoscopic remission, in addition to that clinic,
29:24is very important to define the long-term outcomes
29:27of ulcerative colitis,
29:29as it has been shown that up to 70% of patients
29:32in the long term who reach an endoscopic remission
29:35remain free from ulcerative colitis.
29:38The equally important aspect is that this result
29:41has been documented as positive,
29:44significantly positive,
29:47also in patients who had previously failed
29:50advanced therapies,
29:52and not only in naive patients to biopharmaceuticals.
29:55Guselcumab is being evaluated
29:58by the European Medicinal Agency
30:01for the treatment of adult patients with ulcerative colitis
30:04and Crohn's disease from moderate to serious.
30:07In relation to the record studies on Crohn's disease,
30:10Guselcumab can be positioned for patients
30:13who are bio-naive or bio-exposed.
30:16The effectiveness of 70% from the point of view
30:19of the clinical remission to one year
30:22certainly represents a big target for our patients
30:25with Crohn's disease.
30:31The Federation of Italian Medical Scientific Societies
30:34has inaugurated in Bari, in collaboration with the Ministry of Health,
30:37the Health Village, a three-day dedicated to prevention
30:40and health education.
30:43Until December 1, Piazza Libertà, in the center of the capital Pugliese,
30:46forms a large prevention, information and awareness pool
30:49welcoming citizens in an area of about 1,500 square meters.
30:52The large tensile structure is articulated
30:55between workshop rooms, a multidisciplinary ambulatory,
30:58information stands for a series of pathologies
31:01from cardio-renal metabolic syndrome to Crohn's disease.
31:04An example of synergy between the realities involved,
31:07the Health Village represents a unique opportunity
31:10to spread the culture of prevention,
31:13actively communicating it through free services and moments of confrontation.
31:16The Village is a virtuous model of collaboration
31:19between private and third sector public entities
31:22that have participated and are united by a common goal,
31:25the protection and improvement of the health of citizens.
31:28An applause has also come from the Minister of Health,
31:31Orazio Schillaci, who in a video call spoke of a beautiful
31:34possible initiative thanks to the availability of health professionals
31:37and representatives of the various institutions
31:40of the sector to offer free screenings,
31:43specialist visits and training courses and to raise awareness
31:46of the importance of prevention.
31:49Also present is the Deputy Secretary of Health, Marcello Gemmato,
31:52who received the invitation from the FISM of its President,
31:55Loretto Gesualdo, to carry out this event at the conclusion of the G7 Salute.
31:58We launch a very strong message
32:01on prevention.
32:04The logo of the Health Village is a germ.
32:07We want to germinate here in Bari
32:10the culture of prevention at 360 degrees.
32:18For 19 years alongside health workers,
32:21thus becoming the reference event of Italian health.
32:24It is the Risk Management Forum of Arezzo,
32:27taking place from the 26th to the 29th of November.
32:30During the concluding day,
32:33the agreement was made to rethink the nursing profession,
32:36rethink the national health service,
32:39organized by FNOPI, the National Federation of Nursing Professions,
32:42where among the topics discussed
32:45there was also talk of the change of the national health system
32:48with the introduction of the three new nursing degrees.
32:51We expect an important change,
32:54a change that is aimed above all to qualify even more
32:57the nursing profession in the relationships within the multi-professional team,
33:00therefore with the doctors and with the other components of the team,
33:03but above all to qualify more
33:06the nursing skills in response to the needs of the citizens.
33:09We have been guided by epidemiological and demographic issues.
33:12Italy is a country that is aging in an important way,
33:15we are not aging in good health.
33:18The health and social needs are more and more complex,
33:21more and more articulated,
33:24and therefore there is a need for a highly qualified and specialized
33:27nursing component to make an important contribution
33:30both in this response to the needs of the citizens
33:33and within the professional teams.
33:36We have focused on three master's degrees,
33:39which are the ones that collect most of the assistance settings
33:42at the moment, and above all they are the most strategic,
33:45therefore the whole issue of territorial and primary care,
33:48the issue of neonatal pediatric infirmary,
33:51given also the great demographic problem we have,
33:54and the issue of emergency.
33:57The figure of the nursing assistant is also important
34:00to support the figure of the nurse.
34:03The figure of the nursing assistant is a figure
34:06of health care workers that can complete
34:09the assistance line,
34:12so OS, nurse assistant,
34:15and then the nurse professional who remains
34:18responsible for the nursing assistance.
34:21The issue of the lack of nurses is an international and national issue,
34:24it also concerns Veneto.
34:27Last August we approved an extraordinary plan
34:30to deal with the shortage of nurses,
34:33in particular.
34:36The idea is that the nurse assistant can occupy
34:39an area of basic care,
34:42currently managed directly by the nurse,
34:45to free up nurse time
34:48for skills more appropriate to the figure of the nurse,
34:51so high skills of care,
34:54of education, of empowerment,
34:57of support of the caregiver.
35:04A contribution to the PIL that exceeds 524 million euros,
35:07a total of revenues that in 2023 reached 770 million.
35:10AstraZeneca and Lexion present in Bari
35:13a study by The European House and Brusetti
35:16on the impact that the pharmaceutical sector,
35:19as well as the group, can generate in Italy.
35:22The current economic dimension of AstraZeneca and Lexion
35:25is the result of a constant growth path in the last quarter.
35:28Revenues in Italy have had an increase of 19.5%
35:31from 2019 to 2023.
35:34The growth has been accompanied by an equally virtuous path
35:37in the ability to create added value.
35:40The impact that has been shown is a direct impact
35:43of more than 500 million euros of added value in 2023.
35:47Very important, a multiplier of almost 3,
35:50which means that every euro we have invested
35:53has generated almost 2.7 euros of impact on the country's system.
35:56A weight that also serves as a pull for research.
35:59In this area, the group boasts a leadership
36:02also in the field of rare diseases.
36:05An example is the role of Primo Piano that Lexion plays
36:08in the research on myasthenia gravis,
36:11with over 23% of all experiments in this pathology
36:15Today we have 22 studies abroad in Italy
36:18and we collaborate with 130 centers in Italy
36:21precisely to try to develop new molecules
36:24and new indications.
36:27Ambrosetti, who curated the study,
36:30emphasized how this sector is going through
36:33a phase of strong dynamism.
36:36We must certainly invest to increase the attractiveness
36:39of our country system with targeted investments,
36:42with a vision of an iScience strategy.
36:50More than 900 clinics, the most recent
36:53diagnostic, therapeutic and technological innovations,
36:56the new challenges for the future between innovation and sustainability.
36:59The IGBD, the three-day organized by the Italian group
37:02for the development of inflammatory and chronic intestinal diseases,
37:05took the lead in the 15th National Congress.
37:08We are witnessing a revolution
37:11in clinical practice, experts say,
37:14between advanced therapies, innovations and new smart technologies
37:17such as artificial intelligence and telemonitoring.
37:21We know very well what are the problems
37:24related to costs,
37:27both from a pharmacological point of view
37:30and also from a point of view of endoscopic technology.
37:33All this must lead to a reflection
37:36on the approach that we must have
37:39for our patients, with a particular focus
37:42on interdisciplinarity.
37:45All this in order to improve a system
37:48that can also rationalize costs,
37:51but also increase the performance
37:54of our treatments in trying to reach
37:57more and more the therapeutic objectives
38:00in the therapy of inflammatory and chronic intestinal diseases.
38:03Inflammatory and chronic intestinal diseases
38:06are a group of pathologies characterized
38:09by a chronic inflammation of the gastrointestinal tract
38:12with a significant impact on the patient's life.
38:15Although these diseases can occur at any age,
38:18they occur more frequently among adolescents
38:21and young adults under 35,
38:24with a quarter of the cases even already in the pediatric stage.
38:27Clearly, in addition to the importance of having new drugs available,
38:30the strategies we use are just as important.
38:33In the future, we hope to have available
38:36the so-called biomarkers, so that we can know
38:39if that patient will respond to that type of drug
38:42and that other patient to another type of drug.
38:45So we are always moving towards more personalized medicine
38:48with the main aim of maintaining
38:51the sustainability of the system
38:54and trying to guarantee sustainability
38:57with the costs of these therapies.
39:00The Italian epidemiological data shows
39:03a precise estimate of the socio-economic impact
39:06of inflammatory and chronic intestinal diseases.
39:09In our country, it is estimated,
39:12because we do not have precise numbers,
39:15that there are about 270-300,000 patients
39:18affected by inflammatory and chronic intestinal diseases
39:21and about 7 million are patients who suffer from it
39:24in the world.
39:27A priority of the Foundation is to collect data
39:30on the cases of colitis ulcerosa and Crohn's disease
39:33with the aim of having the most precise photograph possible
39:36in terms of epidemiology and not only
39:39the clinical characteristics of medical treatments
39:42and so on in our country.
39:45The first edition of the One Health Ambassador project
39:48promoted by Boehringer Ingelheim
39:51in collaboration with EDRA
39:54has concluded with the awarding event
39:57at the Senate of the Republic.
40:00The initiative, which involved doctors of general medicine,
40:03pharmacists and veterinarians, aims to promote
40:06an integrated and multidisciplinary approach
40:09to the treatment of chronic diseases
40:12and emphasizing the interconnection
40:15between human, animal and environmental health.
40:18We certainly noticed the need
40:21to increase training,
40:24ensuring better alignment between professions.
40:27As we now say,
40:30One Health is for everyone,
40:33it is not a good thing, but a necessity
40:36and therefore we must continue to make sense of it.
40:39The project, launched in spring,
40:42has mapped virtuous practices and identified professionals
40:45who daily apply the One Health model,
40:48considered essential to face challenges such as zoonoses,
40:51emerging diseases and antibiotic resistance.
40:54Of the 102 awarded, 55% are veterinarians,
40:5728% pharmacists
41:00and 17% doctors of general medicine.
41:03The most represented regions are Lombardy,
41:06Lazio and Emilia-Romagna,
41:09but gaps have emerged in areas at high risk of zoonosis,
41:12suggesting a lower local sensitivity.
41:15The approach is now known to everyone,
41:18it is a holistic approach, a system approach,
41:21an approach that involves environment, therapies,
41:24early diagnosis, early and effective
41:27care, precision medicine,
41:30in short, all topics that open up challenging
41:33and very innovative areas.
41:36The health professions are all transversally involved
41:39in this logic, which I recall
41:42is the logic underlying PNRR.
41:48The report, linked to the initiative,
41:51highlighted the need to intensify training
41:54and interprofessional collaboration.
41:57Veterinarians and pharmacists have expressed the desire
42:00to promote synergy, also through the support
42:03of institutions and scientific societies.
42:06However, criticisms have emerged,
42:09including a lack of knowledge of zoonosis
42:12by many basic doctors and the need for a greater
42:15use of tools such as the antibiogram
42:18to combat antibiotic resistance.
42:21Only in this circularity can we have
42:24a better approach to the protection of our health.
42:27The initiative also highlighted the importance
42:30of raising awareness among the general public
42:33and the new generations about the One Health approach.
42:36The aim is to encourage cultural change
42:39and promote collaboration among professionals
42:42to build a healthy and sustainable society.
42:45The initiative also highlighted the importance
42:48of raising awareness among the general public
42:51and the new generations about the One Health approach.
42:54The aim is to encourage cultural change
42:57and promote collaboration among professionals
43:00to build a healthy and sustainable society.
43:03This was our latest news,
43:06for contacting us you can write to
43:09salutechiocciola.com
43:12Thank you for following us and see you next time!
43:24Thank you for following us and see you next time!